Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Director Saira Ramasastry sold 5,000 shares of the business’s stock in a transaction on Friday, November 17th. The shares were sold at an average price of $14.67, for a total transaction of $73,350.00. Following the completion of the transaction, the director now directly owns 5,000 shares in the company, valued at $73,350. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Sangamo Therapeutics, Inc. (NASDAQ SGMO) traded up $0.40 during trading hours on Tuesday, hitting $15.10. 1,148,624 shares of the stock were exchanged, compared to its average volume of 1,294,677. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.64 and a current ratio of 5.64. Sangamo Therapeutics, Inc. has a fifty-two week low of $2.65 and a fifty-two week high of $17.06.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.04. Sangamo Therapeutics had a negative net margin of 157.66% and a negative return on equity of 31.81%. The business had revenue of $11.81 million for the quarter, compared to analysts’ expectations of $10.37 million. During the same period in the prior year, the company posted ($0.27) EPS. The business’s revenue for the quarter was up 333.0% on a year-over-year basis. equities research analysts expect that Sangamo Therapeutics, Inc. will post -0.79 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Sangamo Therapeutics, Inc. (SGMO) Director Sells $73,350.00 in Stock” was first reported by American Banking News and is owned by of American Banking News. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/11/21/sangamo-therapeutics-inc-sgmo-director-sells-73350-00-in-stock.html.

Several institutional investors have recently added to or reduced their stakes in SGMO. RA Capital Management LLC purchased a new stake in shares of Sangamo Therapeutics in the 2nd quarter worth about $11,000,000. State Street Corp boosted its position in shares of Sangamo Therapeutics by 51.6% in the 2nd quarter. State Street Corp now owns 1,868,285 shares of the biopharmaceutical company’s stock worth $16,441,000 after buying an additional 636,296 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Sangamo Therapeutics by 12.4% in the 2nd quarter. Vanguard Group Inc. now owns 3,471,681 shares of the biopharmaceutical company’s stock worth $30,551,000 after buying an additional 384,031 shares in the last quarter. Balyasny Asset Management LLC purchased a new stake in shares of Sangamo Therapeutics in the 2nd quarter worth about $3,095,000. Finally, American Century Companies Inc. purchased a new stake in shares of Sangamo Therapeutics in the 3rd quarter worth about $5,145,000. Institutional investors and hedge funds own 63.29% of the company’s stock.

Several brokerages have issued reports on SGMO. ValuEngine raised shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. BidaskClub cut shares of Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Wells Fargo & Company reaffirmed an “outperform” rating and set a $30.00 price target (up from $20.00) on shares of Sangamo Therapeutics in a research note on Tuesday, September 5th. Jefferies Group LLC reaffirmed a “buy” rating and set a $18.00 price target on shares of Sangamo Therapeutics in a research note on Friday, October 13th. Finally, Piper Jaffray Companies raised shares of Sangamo Therapeutics from a “neutral” rating to an “overweight” rating and set a $19.00 price target on the stock in a research note on Wednesday, November 15th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $17.40.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Insider Buying and Selling by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.